The study investigates the role of cytosolic thioredoxin-1 in cardiac function and mitochondrial integrity using inducible, cell-specific gene deletion. Cardiomyocyte-specific loss of thioredoxin caused severe myocardial injury, ischemia, infarction and mitochondrial dysfunction. Endothelial-specific deletion impaired nitric oxide production. Recombinant human thioredoxin treatment improved mitochondrial structure and cardiac function in both models.
Cardiomyocyte-specific thioredoxin deletion caused severe myocardial ischemia, infarction, mitochondrial dysfunction and substantial mortality within three weeks. Endothelial deletion reduced nitric oxide production through eNOS dysfunction. Recombinant human thioredoxin restored mitochondrial structure, mitochondrial gene expression, OGG1 activity and cardiac function.
Txn^flox/flox conditional Knockout mouse, carrying a floxed cytosolic thioredoxin-1 allele for Cre-mediated deletion. The mice were crossed with tamoxifen-inducible αMHC-Cre for cardiomyocyte-specific deletion and VE-cadherin-CreERT2 for endothelial-specific deletion. These approaches enabled investigation of thioredoxin function in adult cardiac and vascular cells.
Cardiovascular disease, myocardial infarction, cardiac ischemia, mitochondrial dysfunction, oxidative stress, endothelial dysfunction, redox biology, cardioprotection
Txn conditional Knockout, Txn floxed allele, Cre-LoxP recombination, tamoxifen-inducible deletion, αMHC-Cre, VE-cadherin-CreERT2, cardiomyocyte-specific Knockout, endothelial-specific Knockout, mitochondrial functional analysis, recombinant thioredoxin rescue
モデル設計から実験結果まで
600件以上の科学論文で取り上げられています
大手製薬企業17社、
、170社以上のバイオテクノロジー企業、および380以上の学術機関との提携
バイオ医薬品分野のパートナー企業および 社内リソースを用いて生成
および実施の自由が保証される
米国および欧州の専門ブリーダーから、健康状態が認定された個体
